Predictive Diagnostics – Worldwide Market Outlook Report, 2019: Growth Drivers, Trends and Issues

DUBLIN, April 4, 2019 /PRNewswire/ — The “Predictive Diagnostics – Market Analysis, Trends, and Forecasts” report has been added to’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Predictive Diagnostics in US$ Thousand.

The report profiles 47 companies including many key and niche players such as:

  • Abbott Molecular (USA)
  • Almac Group Ltd. (Ireland)
  • Ambry Genetics Corporation (USA)
  • BioGenex (USA)
  • Epistem Ltd. (UK)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Genomic Health, Inc. (USA)
  • MDxHEALTH, Inc. (USA)
  • Myriad Genetics, Inc. (USA)
  • OPKO Health, Inc. (USA)
  • Prometheus Laboratories Inc. (USA)
  • Proteomics International Laboratories Ltd (Australia)
  • QIAGEN N.V. (The Netherlands)

Key Topics Covered



A Curtain Raiser

Predictive Diagnostics – A Key Segment of Genetic Testing

Outlook for Predictive Diagnostics Market

Prospects for Predictive Genetic Diagnostics Grow Brighter

Oncology: A Key Growth Driver for Predictive Diagnostics

Genes and Associated Cancers/Tumors

Predictive Diagnostics – Crucial for Breast Cancer Management

Inherited Breast Cancer – An Important End-use Market for Predictive Diagnostics

About BRCA1 and BRCA2

Breast Cancer Gene Testing Market to Expand Strongly

Myriad Genetics-The Unquestioned Leader in Breast Cancer Testing

The First FDA-Approved DTC Breast Cancer Genetic Assay

Limitations of Breast Cancer Screening

Growing Popularity of Multi-gene Panels in Clinical Cancer Genetics

Clinical Characteristics of Moderate-High Penetrance Genes Other than BRCA1/2

Challenges Associated with Multigene-Panel Testing

Next-Generation Sequencing – A Giant Leap in Genome Sequencing

Genes Included in NGS Panels

Increasing Incidence of Colorectal Cancer in <_0 age="age" group_="group_" a="a" business="business" case="case" for="for" predictive="predictive" />Growing Number of Colorectal Cancer Risk Population with Lynch Syndrome

Genes Associated with Inherited Risk of Colorectal Cancer

Launch of PromarkerD: Hope for Early Diagnosis of Diabetic Kidney Disease

What is PromarkerD?

Patents for PromarkerD


The BRACAnalysis Assay

Oncotype Dx Prostate Cancer Assay

Myrisk Hereditary Cancer Panel


LifeKit Predict

Prolaris Genetic Test


Breast Cancer Index (BCI) Test

The PancraGEN Assay

Proove Opioid Response Assay

VeriStrat Test

BRAF Mutation Detection Assay

Oncotype Dx Colon Cancer Test

ColoPrint 18-Gene Colon Cancer Recurrence Test
ROMA Assay

Panexia Assay

CytoScan Dx Assay

Oncotype Dx Breast Cancer Assay


Rising Incidence and Prevalence of CDDs: A Major Growth Driver

Increasing Cancer Disease Burden Drives the Demand for Predictive Diagnostics

Incidence of Neurodegenerative Diseases Increasing

Alzheimer’s Disease

Huntington’s Disease

Quick Facts on the Global Prevalence of Huntington’s Disease

Parkinson’s Disease

Ballooning Global Population Offers Significant Growth Opportunities

Predictive Diagnostics Enable Higher Life Expectancy

Widening of Insurance Coverage for Hereditary Cancer Testing

Discovery of Novel Biomarkers – Crucial to Predictive Diagnostics

Genomic Research Remains Confined to Fundamental Research

Unresolved Issues Hamper Widespread Implementation of Genetic Testing for Monogenetic Disease

Dearth of Genetic Counselors – A Major Hurdle for the Predictive Genetic Testing

Framework for Validation, Regulation, and Ethical Issues – The Need of the Hour



Underlying Principles of Predictive Diagnostics

Predictive Diagnostics Vis-a-vis Conventional Testing

Characteristics of an Effective Predictive Diagnostic Test

Applications of Predictive Diagnostics


Predisposition Testing

Cancer Testing

Carrier Identification

Steps in Genetic Testing Process


Risks and Other Limitations of Genetic Testing

Select Diseases Identified Using Predictive Diagnostics

Cystic Fibrosis

Breast and Ovarian Cancer (BRCA)

Alzheimer’s Disease

Colorectal Cancer

Hemochromatosis (HH)

Huntington’s Disease (HD)

Costs of Select Tests

Medical Ethics Surrounding Predictive Diagnostics


6.1 Focus on Select Key Players

6.2 Product Introductions

BaseHealth Introduces First Predictive Analytics Platform

Predictive Diagnostics Introduces Endometriosis Risk Test

Proteomics International Enters into Licensing Agreement with PrismHealthDx for the Launch of PromarkerD Predictive Test in the US

SQI Diagnostics and Predictive Health Diagnostics Introduces Revolutionary Predictive Cardiac Test

QIAGEN Introduces Predictive Therascreen PITX2 Test in Europe

Proteomics International Laboratories Announces the Official Launch of Predictive diagnostic test, PromarkerD

MDxHealth Introduces AssureMDx for Bladder Cancer Liquid Biopsy Test

LabCorp Introduces Sera Prognostics’ PreTRM Test

Proteomics International Laboratories presents an update on commercialisation progress for the PromarkerD test

6.3 Recent Industry Activity

FDA Authorizes First Direct-to-Consumer Genetic Test from 23andMe for Cancer Risk

Proteomics International Agrees with PrismHealthDx for Launching PromarkerD predictive test in the US

Proteomics International Announces the Availability of PromarkerD kit version for Imminent Commercial Release

Proteomics International Collaborates with Janssen to Evaluate PromarkerD Kidney Disease Test

Predictive Technology Group Completes the Acquisition of Inception Dx

Epistem Announces the Completion of Management Buyout

MDxHealth Enters into Worldwide Licencing Agreement with Philips for Prognostic Prostate Cancer Biomarker

Konica Minolta Completes the Acquisition of U.S.-based Ambry Genetics

Color Genomics Receives Investments from High-Profile Investors

SQI Diagnostics Sells Automated Sqidlite Platform to Predictive Cardiac Customer

MDxHealth Associates with Ferrer to Distribute SelectMDx in Spain

Prescient Medicine Acquires PGxL Laboratories


Total Companies Profiled: 47 (including Divisions/Subsidiaries – 48)

  • The United States (27)
  • Canada (1)
  • Europe (15)
    • Germany (4)
    • The United Kingdom (6)
    • Spain (1)
    • Rest of Europe (4)
  • Asia-Pacific (Excluding Japan) (4)
  • Middle East (1)

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links